Cardiff Oncology, Inc. (CRDF) vs Telomir Pharmaceuticals, Inc. Common Stock (TELO)
A side-by-side comparison of Cardiff Oncology, Inc. and Telomir Pharmaceuticals, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CRDF
Cardiff Oncology, Inc.
$1.07HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
TELO
Telomir Pharmaceuticals, Inc. Common Stock
$1.20HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — CRDF vs TELO
growth of $100 · dividends reinvested · last 3yCRDF -28.3% (-10.5%/yr)TELO -82.7% (-44.3%/yr)CRDF compounded faster over this window
CRDF TELO
CRDF vs TELO: by the numbers
- •TELO is the larger company ($83M vs $82M market cap).
- •Both run net losses; TELO's is the smaller (0.00% vs -7884.06% net margin).
Metrics side by side
Valuation
| Metric | CRDF | TELO |
|---|---|---|
| P/S ratio | 162.34 | N/A |
| P/B ratio | 3.11 | 16.40 |
Profitability
| Metric | CRDF | TELO |
|---|---|---|
| Gross margin | 100.00% | 0.00% |
| Operating margin | -8256.32% | 0.00% |
| Net margin | -7884.06% | 0.00% |
| ROE | -150.95% | -116.74% |
| ROIC | -159.30% | -120.93% |
Growth (annualized)
| Metric | CRDF | TELO |
|---|---|---|
| Revenue CAGR (5Y) | 5.15% | N/A |
| Total return CAGR (5Y) | -30.36% | N/A |
Go deeper
Dig into the metrics
Cardiff Oncology ROETelomir Pharmaceuticals, Inc. Common Stock ROECardiff Oncology operating marginTelomir Pharmaceuticals, Inc. Common Stock operating marginCardiff Oncology revenue growthTelomir Pharmaceuticals, Inc. Common Stock revenue growthCardiff Oncology free cash flowTelomir Pharmaceuticals, Inc. Common Stock free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.